TITLE

This antiviral offers new option to HIV patients

AUTHOR(S)
Beyzarov, Elena
PUB. DATE
August 2006
SOURCE
Drug Topics;8/7/2006, Vol. 150 Issue 15, p12
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article features Prezista as the new protease inhibitor. Prezista is under the generic name darunavir. It is prescribed for the treatment of HIV in patients who had experienced antiretroviral treatment. It is designed to tackle viral strains that are resistant to one or more protease inhibitors. It is intended to be administered with ritonavir. Its best potency is served when given in combination with the fusion inhibitor Fuzeon. Findings on the potency of the drug meet the guidelines set by the U.S. Department of Health & Human Services, calling for suppression of HIV in patients who underwent previous treatment. It has been manufactured by Tibotec Therapeutics.
ACCESSION #
21938699

 

Share

Read the Article

Courtesy of NEW JERSEY STATE LIBRARY

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics